Clinical Labors of NeuroCode AG
Wetzlar, D-35578, Germany
NCT Number: NCT03780621
A randomized, double-blind, placebo-controlled, two arm cross-over study to determine whether a specific combination of Andrographis paniculata and Withania somnifera can be regarded as a safe and effective treatment for cognitive deficits.
Looking for future studies?
Notify Me60 year–75 year
All sexes
Interventional
Phase 1
Wetzlar, D-35578, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Combination of Andrographis paniculata and Withania somnifera
Visually identical placebo capsule
Time frame: Four weeks
Responses of electric brain activity as spectral power in 17 different brain regions within 6 specially defined frequency ranges (delta, theta, alpha1, alpha2, beta1 and beta2) during the test of cognitive performance: d2-test for attention (d2-Test), memory test (ME-Test), concentration-performance-test with financial reward (CPT-Test).
EuroPharma, Inc.
Industry
Effects of an Adaptogenic Extract on Electrical Activity of Brain in Elderly Subjects With Cognitive Impairment: a Randomized, Double Blind, Placebo-controlled, Two Arms Cross-over Study.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04032626
Alzheimer Disease, Amyloid Plaque
Phoenix, Arizona, United States
View Trial DetailsNCT05818423
Cognition Disorders, Cognitive Decline
San Francisco, California, United States
View Trial DetailsNCT03536975
Brain Diseases, Central Nervous System Diseases
Elbeuf, France
View Trial DetailsNCT05860127
Arterial Occlusive Diseases, Arteriosclerosis
Farmington, Connecticut, United States
View Trial Details